8] 75/F 72/F 41/F 45/F 41/F L R/MC L R L 4.0 1.five 0.0 0.0 0.0 T2N0M0 T1NxM0 T2NxM0 T1N2M0 T2N0M0 T2N0M0 T2N0M0 T2N0M0 T2NxM0 T3N1M0 T2NxM0 T1NxM0 T3N2M0 T2N1M0 T2N0M0 T1N0M0 T1NxM0 T1NxM0 T1NxM0 T1NxM0 T2NxM0 T3NxM0 T2NxM0 T2NxM0 T2NxM0 T3N0M0 T1N0M0 + + + + + + NS NS NS NS + NS + NS + + NS + + NS + NS L: + R: + + NS L: + R: + NS + + + + + + + + + + + + + + + + + + + + NS NS NS NS NS NS NS Mast/ALND Mast/SLNB BCS BCS BCS HT NS NS NS NS 20 NS 101 80 90 NED NS NED NED NED + + + + + + + + + + + + + BCS/ SLNB Mast/ALND BCS HT Ch Ch 12 NS NS NED NS NS + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + NS NS + + NS + + + + + + + NS NS + NS + + NS NS NS NS NS NS NS NS NS + NS NS NS NS NS NS Ch NS NS Ch Ch Mast/ALND BCS BCS Mast/ALND Mast/ALND Mast Mast/ALND BCS/ALND NS NS Mast BCS BCS BCS Mast/SLNB/Re Mast/SLNB BCS/ALND Mast/ALND Mast/ALND Mast/ALND BCS/ALND BCS/SLNB BCS NS NS NS NS NS Ch HT Ch/RT NS NS HT Ch/RT Ch/RT Ch/RT Ch HT Ch/RT Ch Ch Ch Ch RT RT 54 NS NS NS NS 14 12 18 34 43 NS 48 20 six NS 36 18 9 eight 12 three NS 18 NED NED NED NED NS D-N0S NED NED NED NED AWM NED D-NOS AWM NS NED NED D-NOS NED AWM D-NOS NS NEDAngarita et al. World Journal of Surgical Oncology 2013, 11:128 http://www.wjso/content/11/1/T1N0M0 Both + TisN0M0 TisN0M0 TisN0M0 + + +Page 5 ofTable 1 Summary of primary neuroendocrine carcinoma in the breast cases published in the indexed literature (n=83)a (Continued)74/F 28/F 30/F 58/F 36/F 38/F 60/F 42/F 43/F 35/F 70/F 72/F 62/F 38/F 73/F 43/F 42/F 39/F 33/F 36/F 68/F (2012) [Present case]aAngarita et al. Globe Journal of Surgical Oncology 2013, 11:128 http://www.wjso/content/11/1/R R L R L R L L R R L R L R R L L R R L R R0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.two 0.three 0.4 0.5 0.5 0.7 1.5 two.five 2.TisN0M0 TisN0M0 TisN0M0 TisN0M0 TisN0M0 TisN0M0 T1N0M0 T1N0M0 T1N0M0 T1N0M0 T1N0M0 T1N0M0 T1N0M0 T1N0M0 T1N0M0 T1N1M0 T1N0M0 T1N0M0 T1N0M0 T1N0M0 T2N0M0 T4aN0M+ + + + + + + + + + + + + + + + + + + + + ++ + + + + + + + + + + + + + + + + + + + + ++ + + + + + + + + + + + + + + + + + + + + ++ + + + + + + + + + + + + + + + + + + + + ++ + + + + + + + + + + + + + + + + + + + + -NS NS NS NS NS NS NS NS NS NS NS NS NS NS NS NS NS NS NS NS NS -NS NS NS NS NS NS NS NS NS NS NS NS NS NS NS NS NS NS NS NS NS Ch/RTBCS Mast BCS BCS BCS Mast BCS Mast BCS BCS Mast Mast BCS BCS Mast BCS BCS Mast Mast BCS Mast Mast/ALNDNS NS NS NS NS NS NS NS NS NS NS NS NS NS NS NS NS NS NS NS NS Ch/HT91 77 86 96 64 69 84 73 80 one hundred 93 66 88 85 71 86 96 74 92 99 68NED NED NED NED NED NED NED NED NED NED NED NED NED NED NED NED NED NED NED NED NED AWM51/FStudies included within this table are those available in PubMed as of May 31, 2012.Endoxifen Papers that were excluded from this summary are these in which information was not provided explicitly in the description from the case report or for the reason that the results had been grouped into cohorts [12,49,57].Calcitonin (human) b Obtained either from clinical history or the final pathology report; for multifocal or multicentric disease the biggest tumor was registered.PMID:24982871 ALND, axillary lymph node dissection; AWM, alive with metastatic illness; B, bilateral; BCS, breast conserving surgery; CgA/B, chromogranin A and/or B; Ch, chemotherapy; D-NOS, dead, but lead to not otherwise specified; DOD, dead of other illness; ER, estrogen receptors; F, female; GML, Grimelius staining; HT, hormone therapy; IHC, immunohistochemistry; IS, breast in situ component; LR, neighborhood recurrence; M, male; Mast, mastectomy; MC, multicentric; MF, mul.
bet-bromodomain.com
BET Bromodomain Inhibitor
